Phase 3 Readout

MDGL: Phase 3 Topline: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on L

Name: Phase 3 Topline: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on L
Start: 2027-01-01
End: 2027-01-01

January 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2027
Company: MADRIGAL PHARMACEUTICALS, INC. (MDGL)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on L

January 1, 2027

MDGL overview →

Company: MADRIGAL PHARMACEUTICALS, INC. (MDGL)
Indication: NASH; Cirrhosis, Liver